Article

Digestive Diseases and Sciences

, Volume 41, Issue 12, pp 81S-85S

High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C

A pilot study
  • Wolfgang VogelAffiliated withDepartment of Internal Medicine, District Hospital of SalzburgDepartment of Internal Medicine, District Hospital of LinzDepartment of Internal Medicine, District Hospital of WelsDepartment of Internal Medicine, Innsbruck University
  • , Ivo GraziadeiAffiliated withDepartment of Internal Medicine, District Hospital of SalzburgDepartment of Internal Medicine, District Hospital of LinzDepartment of Internal Medicine, District Hospital of WelsDepartment of Internal Medicine, Innsbruck University
  • , Florian UmlauftAffiliated withDepartment of Internal Medicine, District Hospital of SalzburgDepartment of Internal Medicine, District Hospital of LinzDepartment of Internal Medicine, District Hospital of WelsDepartment of Internal Medicine, Innsbruck University
  • , Christian DatzAffiliated withDepartment of Internal Medicine, District Hospital of SalzburgDepartment of Internal Medicine, District Hospital of LinzDepartment of Internal Medicine, District Hospital of WelsDepartment of Internal Medicine, Innsbruck University
  • , Franz HacklAffiliated withDepartment of Internal Medicine, District Hospital of SalzburgDepartment of Internal Medicine, District Hospital of LinzDepartment of Internal Medicine, District Hospital of WelsDepartment of Internal Medicine, Innsbruck University
  • , Stefan AllingerAffiliated withDepartment of Internal Medicine, District Hospital of SalzburgDepartment of Internal Medicine, District Hospital of LinzDepartment of Internal Medicine, District Hospital of WelsDepartment of Internal Medicine, Innsbruck University
  • , Kurt GrünewaldAffiliated withDepartment of Internal Medicine, District Hospital of SalzburgDepartment of Internal Medicine, District Hospital of LinzDepartment of Internal Medicine, District Hospital of WelsDepartment of Internal Medicine, Innsbruck University
  • , Josef PatschAffiliated withDepartment of Internal Medicine, District Hospital of SalzburgDepartment of Internal Medicine, District Hospital of LinzDepartment of Internal Medicine, District Hospital of WelsDepartment of Internal Medicine, Innsbruck University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Acute hepatitis C takes a chronic course in 50–80% of cases. Results with interferon treatment are conflicting. To evaluate the efficacy of high-dose interferon treatment, we initiated a pilot study in 1992 using 10 MU interferon-α2b administered subcutaneously daily until normalization of serum transaminase concentrations. Treatment was begun when a diagnosis of acute hepatitis C was established. HCV-RNA was tested using PCR prior to treatment, three times weekly during the first two weeks of treatment, and then once weekly until the end of therapy. During the 15-month follow-up, HCV-RNA tests were performed monthly up to month 6 and every two to three months thereafter. Twenty-four patients were enrolled at the time of writing; age ranged from 18 to 76 years (mean=32), and nine patients were men. All patients presented with cholestatic hepatitis; 19 were actively abusing intravenous drugs, four had no known parenteral exposure, and one was a medical laboratory technician. All patients were anti-HCV positive, HCV-RNA positive, and HIV negative. Five patients were infected with genotype 3, five with genotype 1a, five with genotype 1b, three with genotypes 3 and 2, and one with genotypes 1 and 2. All patients exhibited normalized serum transaminase concentrations within 18–43 days; HCV-RNA became negative in all patients within 4–12 days. Toxicity did not exceed grade 1 and disappeared within three days of treatment. In the follow-up period, which ranged from six to 29 months (mean=19.5±10.4), serum ALT concentrations remained normal and HCV-RNA remained negative in all patients except two dropouts and two patients who developed relapsing disease after having been HCV-RNA negative for three and eight months, respectively. In both patients, the same HCV genotype 3 reemerged. Serum ALT concentrations ranged from 531 to 1940 IU/liter (mean=1055; normal <22). Concentrations of HCV-RNA (Quantiplex; Chiron, Emeryville, California) were <3.5×105 eq/ml in nine of 14 PCR-positive patients. In the other five patients, concentrations ranged from 10.4×105 eq/ml to 131.6×105 eq/ml (mean=69.6×105). No correlation was observed between HCV-RNA concentrations and serum ALT concentrations at presentation (r=0.331;P=0.67) and total dose of interferon-α2b administered until normalization of ALT (r=−0.088;P=0.74). Twenty-two of 24 patients completed treatment (two were noncompliant). Of these, 20 achieved a complete response (HCV-RNA negative for at least six months). Two of these patients relapsed, and 18 (90%) remained HCV-RNA negative for 18.65 (±9.7) months. These findings suggest that high-dose interferon-α2b is well tolerated and effective in preventing a chronic course of hepatitis C infection.

Key words

hepatitis C virus high-dose interferon-α2b acute infection chronic infection prevention